GUFICBIO Gufic Biosciences Q4 FY25 results (Jan–Mar 2025) and concall
Gufic Biosciences reported a challenging Q4 FY25 with significant declines in EBITDA and PAT, primarily attributed to the absorption of fixed costs (interest, depreciation, salaries) from the newly capitalized Indore plant. While full-year revenue saw marginal growth, profitability was impacted by these new costs and price erosion in key molecules. Management outlined strategies for Indore's ramp-up, aiming for EBITDA breakeven in FY26 and net profit breakeven in FY27, alongside expansion plans for its Botulinum Toxin and fertility segments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 204 | 208 | 205 |
| EBITDA | 39 | 34 | 27 |
| Net profit | 22 | 19 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
